Prevalence of combined prothrombotic defects in childhood venous thrombosis in relation to recurrence status
| Combined defects (n = 62) . | Prevalence n (%) in all patients (n = 301) . | Prevalence n (%) in patients without recurrent VTE (n = 237) . | Prevalence n (%) in patients with recurrent VTE (n = 64) . | Prevalance (%) of recurrent VTE in carriers . |
|---|---|---|---|---|
| FV 1691AA | 7 (2.3) | 5 (2.1) | 2 (3.1) | 2/7 (28.6) |
| FV 1691AA/GA and | 39 (12.9) | 15 (6.3) | 24 (37.5) | 24/39 (61.5) |
| Elevated Lp(a) | 16 | 6 | 10 | |
| Protein S def | 10 | 4 | 6 | |
| Antithrombin def | 6 | 3 | 3 | |
| Protein C def | 3 | — | 3 | |
| PT 20210GA | 4 | 2 | 2 | |
| Elevated Lp(a) and | 12 (4.0) | 9 (3.4) | 4 (6.3) | 4/12 (33.3) |
| Protein C def | 7 | 6 | 1 | |
| PT 20210GA | 3 | 1 | 2 | |
| Antithrombin def | 1 | — | 1 | |
| Protein S def | 1 | 1 | — | |
| Protein C def and | 4 (1.3) | 4 (1.7) | — | — |
| Protein S def | 4 | 4 | — | |
| Total | 62 (20.6) | 32 (13.5) | 30 (46.9) | 30/62 (48.4) |
| Combined defects (n = 62) . | Prevalence n (%) in all patients (n = 301) . | Prevalence n (%) in patients without recurrent VTE (n = 237) . | Prevalence n (%) in patients with recurrent VTE (n = 64) . | Prevalance (%) of recurrent VTE in carriers . |
|---|---|---|---|---|
| FV 1691AA | 7 (2.3) | 5 (2.1) | 2 (3.1) | 2/7 (28.6) |
| FV 1691AA/GA and | 39 (12.9) | 15 (6.3) | 24 (37.5) | 24/39 (61.5) |
| Elevated Lp(a) | 16 | 6 | 10 | |
| Protein S def | 10 | 4 | 6 | |
| Antithrombin def | 6 | 3 | 3 | |
| Protein C def | 3 | — | 3 | |
| PT 20210GA | 4 | 2 | 2 | |
| Elevated Lp(a) and | 12 (4.0) | 9 (3.4) | 4 (6.3) | 4/12 (33.3) |
| Protein C def | 7 | 6 | 1 | |
| PT 20210GA | 3 | 1 | 2 | |
| Antithrombin def | 1 | — | 1 | |
| Protein S def | 1 | 1 | — | |
| Protein C def and | 4 (1.3) | 4 (1.7) | — | — |
| Protein S def | 4 | 4 | — | |
| Total | 62 (20.6) | 32 (13.5) | 30 (46.9) | 30/62 (48.4) |
VTE indicates venous thromboembolism; FV, factor V; Lp(a), lipoprotein (a); def, deficiency; PT, prothrombin.